Recruiting
Phase 2

VSJ-110

Sponsor:

Vanda Pharmaceuticals

Code:

NCT07179055

Conditions

Dry Eye

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

VSJ-110

Placebo

Study Details

Brief summary:

The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of dry eye.

Conditions

Dry Eye

Study ID

NCT07179055

Start date

Oct, 2025

Status verified date

Sep, 2025

Completion date

Sep, 2026

Anticipated

Primary completion date

Sep, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Be at least 18 years of age of either gender and any race.
  • Provide written informed consent and sign the HIPAA form.
  • Be willing and able to follow all instructions and attend all study visits.

Exclusion Criteria:

  • Use of any of the disallowed medications during the washout and study period.

Study Design

Enrollment

160 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: VSJ-110 Solution

placebo comparator: Placebo Solution

Interventions

VSJ-110

ophthalmic solution

Placebo

ophthalmic solution

Primary outcome measure

  • Corneal Staining [ Time Frame: Measured over an 8-week treatment period ]

Central Contacts and Locations

Central contacts

Vanda Pharmaceuticals

202-734-3400clinicaltrials@vandapharma.com

Locations

Vanda Investigational Site

Recruiting

Newport Beach, California, United States, 92663

Contacts

Vanda Pharmaceuticals

202-734-3400

Vanda Investigational Site

Recruiting

Memphis, Tennessee, United States, 38119

Contacts

Vanda Pharmaceuticals

202-734-3400

More Information

Sponsor

Vanda Pharmaceuticals

Last update posted

Sep 17, 2025

Last verified

Sep, 2025

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Vanda Pharmaceuticals on 2025-09-17.